PMID- 15795534
OWN - NLM
STAT- MEDLINE
DCOM- 20050927
LR  - 20220411
IS  - 0957-5235 (Print)
IS  - 0957-5235 (Linking)
VI  - 16
IP  - 3
DP  - 2005 Apr
TI  - Effects of pre-analytical variables on the anti-activated factor X chromogenic 
      assay when monitoring unfractionated heparin and low molecular weight heparin 
      anticoagulation.
PG  - 173-6
AB  - The purpose of this study was to determine whether the anti-activated factor X 
      (anti-FXa) assay is less affected by pre-analytical variables in monitoring 
      patients on unfractionated heparin (UFH) and low molecular weight heparin (LMWH) 
      than the activated partial thromboplastin time (aPTT). Forty-six subjects 
      receiving either enoxaparin (LMWH) or UFH were randomly selected. Each study 
      subject had six vacutainer tubes (3.8% sodium citrate, 3.2% sodium citrate) drawn 
      by an atraumatic venipuncture. One tube from each set had a blood to 
      anticoagulant ratio of 9: 1. The other tube had an intentional "short-draw" of 
      approximately 6: 1 blood to anticoagulant ratio. All specimens had an aPTT and a 
      chromogenic anti-FXa assay performed on each specimen regardless of heparin type. 
      The aPTT assay mean with the 3.8% sodium citrate tube short-draw tube was 
      statistically different from the other aPTT assays (P = 0.06). However, all six 
      of the mean anti-FXa assays for the UFH and LMWH heparin subjects were not 
      statistically or clinically different (analysis of variance, P = 0.9878 for UFH 
      and P = 0.9060 for LMWH). The intentional short-draw tube did not affect the 
      anti-FXa assay regardless of the anticoagulant. The anti-FXa assay appears to be 
      a better method for monitoring heparin subjects than the aPTT due to the lack of 
      effect of pre-analytical variables.
FAU - McGlasson, David L
AU  - McGlasson DL
AD  - 59th Clinical Research Squadron, Wilford Hall Medical Center, 2200 Berquist 
      Drive, Lackland AFB, TX 78236-5300, USA. david.mcglasson@lackland af.mil
FAU - Kaczor, Daniel A
AU  - Kaczor DA
FAU - Krasuski, Richard A
AU  - Krasuski RA
FAU - Campbell, Charles L
AU  - Campbell CL
FAU - Kostur, Maria R
AU  - Kostur MR
FAU - Adinaro, Joseph T
AU  - Adinaro JT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Blood Coagul Fibrinolysis
JT  - Blood coagulation & fibrinolysis : an international journal in haemostasis and 
      thrombosis
JID - 9102551
RN  - 0 (Anticoagulants)
RN  - 0 (Chromogenic Compounds)
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9001-29-0 (Factor X)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage
MH  - Blood Coagulation Tests
MH  - Chromogenic Compounds/chemistry
MH  - *Drug Monitoring
MH  - Enoxaparin/administration & dosage
MH  - Factor X/*analysis/antagonists & inhibitors
MH  - Female
MH  - Heparin/*administration & dosage
MH  - Heparin, Low-Molecular-Weight/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time/methods
EDAT- 2005/03/30 09:00
MHDA- 2005/09/28 09:00
CRDT- 2005/03/30 09:00
PHST- 2005/03/30 09:00 [pubmed]
PHST- 2005/09/28 09:00 [medline]
PHST- 2005/03/30 09:00 [entrez]
AID - 00001721-200504000-00002 [pii]
AID - 10.1097/01.mbc.0000164424.90545.6e [doi]
PST - ppublish
SO  - Blood Coagul Fibrinolysis. 2005 Apr;16(3):173-6. doi: 
      10.1097/01.mbc.0000164424.90545.6e.